- Home
- KHC vs MRNA Comparison
KHC vs MRNA Comparison
Compare KHC & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KHC | MRNA |
|---|---|---|
| Founded | 1869 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8B | 26.7B |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KHC | MRNA |
|---|---|---|
| Price | $25.49 | $133.75 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 17 | 12 |
| Target Price | $24.50 | ★ $34.27 |
| AVG Volume (30 Days) | ★ 14.0M | 12.7M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | ★ 7.14% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,942,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | N/A | $9.36 |
| Revenue Next Year | $0.58 | $15.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $21.04 | $22.28 |
| 52 Week High | $28.10 | $176.66 |
Technical Indicators
Market Signals| Indicator | KHC | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 69.79 |
| Support Level | $25.17 | $41.01 |
| Resistance Level | $25.76 | N/A |
| Average True Range (ATR) | 0.70 | 9.39 |
| MACD | -0.08 | 9.21 |
| Stochastic Oscillator | 46.78 | 65.07 |
Price Performance
Historical ComparisonAbout KHC The Kraft Heinz Company
In July 2015, Kraft merged with Heinz to create one of North America's largest food and beverage manufacturers. Beyond its namesake brands, its portfolio includes Oscar Mayer, Velveeta, and Philadelphia. While the retail channel drives around 85% of its total sales, the firm also maintains a growing foodservice presence. Outside North America, Kraft Heinz's global reach encompasses a distribution network in Europe and emerging markets, which accounts for around 25% of its consolidated sales base. The company's products are sold in more than 190 countries and territories.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.